The ERK1/2 inhibitor U0126 attenuates diabetes-induced upregulation of MMP-9 and biomarkers of inflammation in the retina

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Mohammad, Ghulam ^a   Mairaj Siddiquei, Mohammad ^a   Imtiaz Nawaz, Mohammad ^a   Abu El Asrar, Ahmed M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BIOLOGICAL MARKER; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84879325249     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/658548     Document Type: Article

References (59)

1. Hammes H. P., Feng Y., Pfister F., Brownlee M., Diabetic retinopathy: targeting vasoregression. Diabetes 2011 60 1 9 16 2-s2.0-78751552517 10.2337/db10-0454
2. Calcutt N. A., Cooper M. E., Kern T. S., Schmidt A. M., Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 2009 8 5 417 429 2-s2.0-65449151412 10.1038/nrd2476
3. Frank R. N., Diabetic retinopathy. The New England Journal of Medicine 2004 350 1 48 58 2-s2.0-0348048874 10.1056/NEJMra021678 (Pubitemid 38032183)
4. Gariano R. F., Gardner T. W., Retinal angiogenesis in development and disease. Nature 2005 438 7070 960 966 2-s2.0-30744476478 10.1038/nature04482 (Pubitemid 43093962)
5. El-Asrar A. M., Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East African Journal of Ophthalmology 2012 19 1 70 74
6. Rangasamy S., McGuire P. G., Das A., Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East African Journal of Ophthalmology 2012 19 10 52 59
7. Mohammad G., Siddiquei M. M., Othman A., Al-Shabrawey M., Abu El-Asrar A. M.,. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Experimental Eye Research 2012 107 101 109
8. Abu El-Asrar A. M., Struyf S., Kangave D., Geboes K., van Damme J., Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. The European Cytokine Network 2006 17 3 155 165 2-s2.0-39049193307
9. Arjamaa O., Pöllönen M., Kinnunen K., Ryhänen T., Kaarniranta K.,. Increased IL-6 levels are not related to NF- B or HIF-1 α transcription factors activity in the vitreous ofproliferative diabetic retinopathy. Journal of Diabetes and Its Complications 2011 25 6 393 397
10. Joussen A. M., Poulaki V., Le M. L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T. S., Adamis A. P., A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB Journal 2004 18 12 1450 1452 2-s2.0-7044228789 10.1096/fj.03-1476fje (Pubitemid 39561611)
11. Abu El-Asrar A. M., Desmet S., Meersschaert A., Dralands L., Missotten L., Geboes K., Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. American Journal of Ophthalmology 2001 132 4 551 556 2-s2.0-0034810383 10.1016/S0002-9394(01)01127-8 (Pubitemid 32904579)
12. Demircan N., Safran B. G., Soylu M., Ozcan A. A., Sizmaz S., Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 2006 20 12 1366 1369 2-s2.0-33845546564 10.1038/sj.eye.6702138 (Pubitemid 44921137)
13. Mohammad G., Kowluru R. A., Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. Journal of Cellular Physiology 2012 227 3 1052 1061
14. Yar A. S., Menevse S., Dogan I., Alp E., Ergin V., Cumaoglu A., Aricioglu A., Ekmekci A., Menevse A., Investigation of ocular neovascularization-related genes and oxidative stress in diabetic rat eye tissues after resveratrol treatment. Journal of Medicinal Food 2012 15 4 391 398
15. Kowluru R. A., Mohammad G., dos Santos J. M., Zhong Q., Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 2011 60 11 3023 3033
16. Descamps F. J., Martens E., Kangave D., Struyf S., Geboes K., Van Damme J., Opdenakker G., Abu El-Asrar A. M., The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Experimental Eye Research 2006 83 2 401 407 2-s2.0-33744918292 10.1016/j.exer.2006.01.017 (Pubitemid 43850955)
17. Giebel S. J., Menicucci G., McGuire P. G., Das A., Matrix metalloproteinases in early diabetic retinopathy and their role in alternation of the blood-retinal barrier. Laboratory Investigation 2005 85 5 597 607 2-s2.0-18744362465 10.1038/labinvest.3700251 (Pubitemid 40675441)
18. Nagase H., Woessner J. F., Matrix metalloproteinases. Journal of Biological Chemistry 1999 274 21491 21494 (Pubitemid 129519680)
19. Uemura S., Matsushita H., Li W., Glassford A. J., Asagami T., Lee K. H., Harrison D. G., Tsao P. S., Diabetes mellitus enhances vascular matrix metalloproteinase activity role of oxidative stress. Circulation Research 2001 88 12 1291 1298 2-s2.0-0035933381 (Pubitemid 32587846)
20. Kadoglou N. P., Daskalopoulou S. S., Perrea D., Liapis C. D., Matrix metalloproteinases and diabetic vascular complications. Angiology 2005 56 2 173 189 2-s2.0-15544388564 10.1177/000331970505600208 (Pubitemid 40404472)
21. Cruz-Munoz W., Khokha R., The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Critical Reviews in Clinical Laboratory Sciences 2008 45 3 291 338 (Pubitemid 351883130)
22. Jin M., Kashiwagi K., Iizuka Y., Tanaka Y., Imai M., Tsukahara S., Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001 21 1 28 33 2-s2.0-0035124888 (Pubitemid 32151759)
23. Abu El-Asrar A. M., Dralands L., Veckeneer M., Geboes K., Missotten L., Van Aelst I., Opdenakker G., Gelatinase B in proliferative vitreoretinal disorders. The American Journal of Ophthalmology 1998 125 6 844 851 2-s2.0-0032101677 10.1016/S0002-9394(98)00041-5 (Pubitemid 28283745)
24. Kowluru R. A., Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras. Investigative Ophthalmology and Visual Science 2010 51 8 4320 4326 2-s2.0-77955865427 10.1167/iovs.09-4851
25. Liu P., Wilson M. J., miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF- B factor in human fibrosarcoma cells. Journal of Cellular Physiology 2012 227 2 867 876
26. Lakka S. S., Jasti S. L., Gondi C., Boyd D., Chandrasekar N., Dinh D. H., Olivero W. C., Gujrati M., Rao J. S., Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 2002 21 36 5601 5608 2-s2.0-0037103912 10.1038/sj.onc.1205646 (Pubitemid 34983550)
27. Cho A., Graves J., Reidy M. A., Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 12 2527 2532 2-s2.0-0033663865
28. Ye X., Xu G., Chang Q., Fan J., Sun Z., Qin Y., Jiang A. C., ERK1/2 signaling pathways involved in VEGF release in diabetic rat retina. Investigative Ophthalmology and Visual Science 2010 51 10 5226 5233 2-s2.0-77956231461 10.1167/iovs.09-4899
29. Barouch F. C., Miyamoto K., Allport J. R., Fujita K., Bursell S. E., Aiello L. P., Luscinskas F. W., Adamis A. P., Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Investigative Ophthalmology and Visual Science 2000 41 5 1153 1158 2-s2.0-0034114618 (Pubitemid 30187554)
30. Qaum T., Xu Q., Joussen A. M., Clemens M. W., Qin W., Miyamoto K., Hassessian H., Wiegand S. J., Rudge J., Yancopoulos G. D., Adamis A. P., VEGF-initiated blood-retinal barrier breakdown in early diabetes. Investigative Ophthalmology and Visual Science 2001 42 10 2408 2413 2-s2.0-0034854865 (Pubitemid 32848873)
31. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hämmerling G., Opdenakker G., Arnold B., Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. Journal of Clinical Investigation 1999 104 11 1507 1515 (Pubitemid 30002362)
32. Neary J. T., MARK cascades in cell growth and death. News in Physiological Sciences 2007 12 6 286 293 2-s2.0-0039269178
33. Chen R. H., Sarnecki C., Blenis J., Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Molecular and Cellular Biology 1992 12 3 915 927 2-s2.0-0026608787
34. Lenormand P., Sardet C., Pages G., L'Allemain G., Brunet A., Pouyssegur J., Growth factors induce nuclear translocation of MAP kinases (p42(mapk) and p44(mapk)) but not their activator MAP kinase kinase (p45(mapkk)) in fibroblasts. Journal of Cell Biology 1993 122 5 1079 1088 2-s2.0-0027283659 (Pubitemid 23254175)
35. Abu El-Asrar A. M., Dralands L., Missotten L., Al-Jadaan I. A., Geboes K., Expression of apoptosis markers in the retinas of human subjects with diabetes. Investigative Ophthalmology and Visual Science 2004 45 8 2760 2766 2-s2.0-3242884227 10.1167/iovs.03-1392 (Pubitemid 38998875)
36. Khan Z. A., Chakrabarti S., Cellular signaling and potential new treatment targets in diabetic retinopathy. Experimental Diabetes Research 2007 2007 article 31867 2-s2.0-41149155362
37. Mohammad G., Siddiquei M. M., Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. Journal of Ocular Biology, Diseases, and Informatics 2012 5 1 1 8 10.1007/s12177-012-9091-0
38. Mohammad G., Kowluru R. A., The role of Raf-1 kinase in diabetic retinopathy. Expert Opinion on Therapeutic Targets 2011 15 4 357 364 2-s2.0-79952642466 10.1517/14728222.2011.553604
39. Jo S. K., Cho W. Y., Sung S. A., Kim H. K., Won N. H., MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney International 2005 67 2 458 466 2-s2.0-12344324705 10.1111/j.1523-1755.2005.67102.x (Pubitemid 40139837)
40. Junttila M. R., Li S. P., Westermarck J., Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB Journal 2008 22 4 954 965 2-s2.0-41549160315 10.1096/fj.06-7859rev (Pubitemid 351519953)
41. Ardi V. C., Kupriyanova T. A., Deryugina E. I., Quigley J. P., Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2007 104 51 20262 20267 2-s2.0-38049177345 10.1073/pnas.0706438104
42. Ardi V. C., van den Steen P. E., Opdenakker G., Schweighofer B., Deryugina E. I., Quigley J. P., Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. Journal of Biological Chemistry 2009 284 38 25854 25866 2-s2.0-70350029581 10.1074/jbc.M109.033472
43. 1/2 activation and translocation of NF- B in rat primary astrocyte. Brain Research 2007 1186 1 12 20 2-s2.0-36749071696 10.1016/j.brainres.2007.10.018 (Pubitemid 350214465)
44. Zheng L., Howell S. J., Hatala D. A., Huang K., Kern T. S., Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007 56 2 337 345 2-s2.0-33847037432 10.2337/db06-0789
45. Du Y., Sarthy V. P., Kern T. S., Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2004 287 4 R735 R741 2-s2.0-4644243657 10.1152/ajpregu.00080.2003 (Pubitemid 39280457)
46. Carmo A., Cunha-Vaz J. G., Carvalho A. P., Lopes M. C., Effect of cyclosporin-A on the blood-retinal barrier permeability in streptozotocin- induced diabetes. Mediators of Inflammation 2000 9 5 243 248 2-s2.0-0034531053 10.1080/09629350020025764 (Pubitemid 32055503)
47. Zheng L., Szabó C., Kern T. S., Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor- B. Diabetes 2004 53 11 2960 2967 2-s2.0-7044229731 10.2337/diabetes.53. 11.2960 (Pubitemid 39425922)
48. Joussen A. M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S. J., Rudge J., Yancopoulos G. D., Adamis A. P., Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. The American Journal of Pathology 2002 160 2 501 509 2-s2.0-0036174019 (Pubitemid 34160327)
49. Joussen A. M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., Adamis A. P., Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. The FASEB Journal 2002 16 3 438 440 2-s2.0-0036517850
50. Arai K., Lee S. R., Lo E. H., Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. GLIA 2003 43 3 254 264 2-s2.0-0041363324 10.1002/glia.10255 (Pubitemid 37047681)
51. Wang L., Zheng G. Z., Rui L. Z., Gregg S. R., Hozeska-Solgot A., LeTourneau Y., Wang Y., Chopp M., Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin- activated endothelial cells promote neural progenitor cell migration. Journal of Neuroscience 2006 26 22 5996 6003 2-s2.0-33745271531 10.1523/JNEUROSCI.5380-05.2006 (Pubitemid 44318365)
52. Young H. R., Chung C. P., Oeser A., Solus J., Asanuma Y., Sokka T., Pincus T., Raggi P., Gebretsadik T., Shintani A., Stein C. M., Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Care and Research 2009 61 11 1580 1585 2-s2.0-70449515416 10.1002/art.25009
53. Miyamoto K., Khosrof S., Bursell S. E., Rohan R., Murata T., Clermont A. C., Aiello L. P., Ogura Y., Adamis A. P., Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America 1999 96 19 10836 10841 2-s2.0-0032863021 10.1073/pnas.96.19.10836 (Pubitemid 29442230)
54. van Beijnum J. R., Buurman W. A., Griffioen A. W., Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008 11 1 91 99 2-s2.0-41049117932 10.1007/s10456-008-9093-5
55. Ellis E. A., Guberski D. L., Hutson B., Grant M. B., Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/Wor rat. Nitric Oxide 2002 6 3 295 304 2-s2.0-0036334679 10.1006/niox.2001.0419 (Pubitemid 34852373)
56. Gao B., Calhoun K., Fang D., The proinflammatory cytokines IL-1 β and TNF- α induce the expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway. Arthritis Research and Therapy 2006 8 6, article R172 2-s2.0-67651142330 10.1186/ar2081
57. Firestein G. S., Manning A. M., Signal transduction and transcription factors in rheumatic disease. Arthritis & Rheumatism 1999 42 4 609 621 (Pubitemid 29171980)
58. Maddahi A., Edvinsson L., Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. Journal of Neuroinflammation 2010 7, article 14 2-s2.0-77949396869 10.1186/1742-2094-7-14
59. Woo M. S., Park J. S., Choi I. Y., Kimf W. K., Kim H. S., Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. Journal of Neurochemistry 2008 106 2 770 780 2-s2.0-51649102877 10.1111/j.1471-4159.2008.05430.x